Scilex Holding Co

Scilex Holding Co has a negative net equity of -$207.8 million and a current ratio of 0.08, indicating significant liquidity constraints. The company's cash and equivalents amount to only $4.96 million, while its long-term debt stands at $117.7 million. The enterprise value to revenue ratio is 5.55, which is relatively high for a company with negative operating and net income. The company's profitability is severely challenged, with a net loss of $358.7 million and an operating loss of $353.4 million. Return on equity is 1.73%, and return on assets is -9.83%, both of which are well below industry norms. The gross profit margin is 65.0%, but this is insufficient to offset the high operating expenses. Scilex's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company does not provide segment-specific revenue breakdowns, making it difficult to assess the contribution of different therapeutic areas or markets to overall performance. The company's growth trajectory is negative, with a net loss and declining cash flow. Free cash flow is -$429.95 million, and capital expenditures are -$16.77 million. Analysts have recorded a revenue of $30.25 million and an EPS of -$32.97, reflecting the company's financial distress. The risk assessment indicates medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. The dilution potential is low, but the company's financial instability could lead to future equity offerings. Recent financial filings and transcripts show a continued focus on cost management and debt restructuring. The company has not disclosed any major new product launches or partnerships that could significantly alter its financial trajectory.